Header Logo
Keywords
Last Name
Institution
Announcement

You can now add alternative names! Click here to add other names that you've published under.
 Back to Details

Connection

Martin Cannon to Humans

This is a "connection" page, showing publications Martin Cannon has written about Humans.

 
Connection Strength
  
 
 
0.363
  
  1. Block MS, Dietz AB, Gustafson MP, Kalli KR, Erskine CL, Youssef B, Vijay GV, Allred JB, Pavelko KD, Strausbauch MA, Lin Y, Grudem ME, Jatoi A, Klampe CM, Wahner-Hendrickson AE, Weroha SJ, Glaser GE, Kumar A, Langstraat CL, Solseth ML, Deeds MC, Knutson KL, Cannon MJ. Th17-inducing autologous dendritic cell vaccination promotes antigen-specific cellular and humoral immunity in ovarian cancer patients. Nat Commun. 2020 10 14; 11(1):5173.
    View in: PubMed
    Score: 0.031
  2. Cannon MJ, Block MS, Morehead LC, Knutson KL. The evolving clinical landscape for dendritic cell vaccines and cancer immunotherapy. Immunotherapy. 2019 02; 11(2):75-79.
    View in: PubMed
    Score: 0.027
  3. Goyne HE, Stone PJ, Burnett AF, Cannon MJ. Ovarian tumor ascites CD14+ cells suppress dendritic cell-activated CD4+ T-cell responses through IL-10 secretion and indoleamine 2,3-dioxygenase. J Immunother. 2014 Apr; 37(3):163-9.
    View in: PubMed
    Score: 0.020
  4. Cannon MJ, Goyne HE, Stone PJ, Macdonald LJ, James LE, Cobos E, Chiriva-Internati M. Modulation of p38 MAPK signaling enhances dendritic cell activation of human CD4+ Th17 responses to ovarian tumor antigen. Cancer Immunol Immunother. 2013 May; 62(5):839-49.
    View in: PubMed
    Score: 0.018
  5. Goyne H, Stone PJ, Cannon MJ. Combinatorial strategies for alleviation of tumor-associated immune suppression and therapeutic vaccination against ovarian cancer. Immunotherapy. 2011 Jul; 3(7):805-7.
    View in: PubMed
    Score: 0.016
  6. Chiriva-Internati M, Cobos E, Cannon MJ. Prospects and challenges for immunotherapy of ovarian cancer--what can we learn from the tumor microenvironment? Int Rev Immunol. 2011 Apr-Jun; 30(2-3):67-70.
    View in: PubMed
    Score: 0.016
  7. Chiriva-Internati M, Mirandola L, Kast WM, Jenkins MR, Cobos E, Cannon MJ. Understanding the cross-talk between ovarian tumors and immune cells: mechanisms for effective immunotherapies. Int Rev Immunol. 2011 Apr-Jun; 30(2-3):71-86.
    View in: PubMed
    Score: 0.016
  8. Cannon MJ, Goyne H, Stone PJ, Chiriva-Internati M. Dendritic cell vaccination against ovarian cancer--tipping the Treg/TH17 balance to therapeutic advantage? Expert Opin Biol Ther. 2011 Apr; 11(4):441-5.
    View in: PubMed
    Score: 0.016
  9. Cannon MJ, O'Brien TJ. Cellular immunotherapy for ovarian cancer. Expert Opin Biol Ther. 2009 Jun; 9(6):677-88.
    View in: PubMed
    Score: 0.014
  10. Santin AD, Bellone S, Palmieri M, Zanolini A, Ravaggi A, Siegel ER, Roman JJ, Pecorelli S, Cannon MJ. Human papillomavirus type 16 and 18 E7-pulsed dendritic cell vaccination of stage IB or IIA cervical cancer patients: a phase I escalating-dose trial. J Virol. 2008 Feb; 82(4):1968-79.
    View in: PubMed
    Score: 0.013
  11. Santin AD, Bellone S, Palmieri M, Ravaggi A, Romani C, Tassi R, Roman JJ, Burnett A, Pecorelli S, Cannon MJ. HPV16/18 E7-pulsed dendritic cell vaccination in cervical cancer patients with recurrent disease refractory to standard treatment modalities. Gynecol Oncol. 2006 Mar; 100(3):469-78.
    View in: PubMed
    Score: 0.011
  12. Bondurant KL, Crew MD, Santin AD, O'Brien TJ, Cannon MJ. Definition of an immunogenic region within the ovarian tumor antigen stratum corneum chymotryptic enzyme. Clin Cancer Res. 2005 May 01; 11(9):3446-54.
    View in: PubMed
    Score: 0.011
  13. Cannon MJ, Santin AD, O'Brien TJ. Immunological treatment of ovarian cancer. Curr Opin Obstet Gynecol. 2004 Feb; 16(1):87-92.
    View in: PubMed
    Score: 0.010
  14. Luo Y, Shreeder B, Jenkins JW, Shi H, Lamichhane P, Zhou K, Bahr DA, Kurian S, Jones KA, Daum JI, Dutta N, Necela BM, Cannon MJ, Block MS, Knutson KL. Th17-inducing dendritic cell vaccines stimulate effective CD4 T cell-dependent antitumor immunity in ovarian cancer that overcomes resistance to immune checkpoint blockade. J Immunother Cancer. 2023 11; 11(11).
    View in: PubMed
    Score: 0.010
  15. Khanolkar A, Fu Z, Underwood LJ, Bondurant KL, Rochford R, Cannon MJ. CD4+ T cell-induced differentiation of EBV-transformed lymphoblastoid cells is associated with diminished recognition by EBV-specific CD8+ cytotoxic T cells. J Immunol. 2003 Mar 15; 170(6):3187-94.
    View in: PubMed
    Score: 0.009
  16. Conrad SJ, Raza T, Peterson EA, Liem J, Connor R, Nounamo B, Cannon M, Liu J. Myxoma virus lacking the host range determinant M062 stimulates cGAS-dependent type 1 interferon response and unique transcriptomic changes in human monocytes/macrophages. PLoS Pathog. 2022 09; 18(9):e1010316.
    View in: PubMed
    Score: 0.009
  17. Cannon MJ, O'Brien TJ, Underwood LJ, Crew MD, Bondurant KL, Santin AD. Novel target antigens for dendritic cell-based immunotherapy against ovarian cancer. Expert Rev Anticancer Ther. 2002 Feb; 2(1):97-105.
    View in: PubMed
    Score: 0.008
  18. Lamichhane P, Karyampudi L, Shreeder B, Krempski J, Bahr D, Daum J, Kalli KR, Goode EL, Block MS, Cannon MJ, Knutson KL. IL10 Release upon PD-1 Blockade Sustains Immunosuppression in Ovarian Cancer. Cancer Res. 2017 12 01; 77(23):6667-6678.
    View in: PubMed
    Score: 0.006
  19. Allam H, Johnson BP, Zhang M, Lu Z, Cannon MJ, Abbott KL. The glycosyltransferase GnT-III activates Notch signaling and drives stem cell expansion to promote the growth and invasion of ovarian cancer. J Biol Chem. 2017 09 29; 292(39):16351-16359.
    View in: PubMed
    Score: 0.006
  20. Kieber-Emmons T, Pennisi A, Lane A, Siegel E, Cannon M, Monzavi-Karbassi B, Makhoul I. Defining and managing expectations for early immunotherapy cancer trials. Rev Recent Clin Trials. 2015; 10(1):47-60.
    View in: PubMed
    Score: 0.005
  21. Mirandola L, Yu Y, Cannon MJ, Jenkins MR, Rahman RL, Nguyen DD, Grizzi F, Cobos E, Figueroa JA, Chiriva-Internati M. Galectin-3 inhibition suppresses drug resistance, motility, invasion and angiogenic potential in ovarian cancer. Gynecol Oncol. 2014 Dec; 135(3):573-9.
    View in: PubMed
    Score: 0.005
  22. Kim KH, Greenfield WW, Cannon MJ, Coleman HN, Spencer HJ, Nakagawa M. CD4+ T-cell response against human papillomavirus type 16 E6 protein is associated with a favorable clinical trend. Cancer Immunol Immunother. 2012 Jan; 61(1):63-70.
    View in: PubMed
    Score: 0.004
  23. Chiriva-Internati M, Mirandola L, Yu Y, Jenkins MR, Gornati R, Bernardini G, Gioia M, Chiaramonte R, Cannon MJ, Kast WM, Cobos E. Cancer testis antigen, ropporin, is a potential target for multiple myeloma immunotherapy. J Immunother. 2011 Jul-Aug; 34(6):490-9.
    View in: PubMed
    Score: 0.004
  24. Chiriva-Internati M, Yu Y, Mirandola L, D'Cunha N, Hardwicke F, Cannon MJ, Cobos E, Kast WM. Identification of AKAP-4 as a new cancer/testis antigen for detection and immunotherapy of prostate cancer. Prostate. 2012 Jan; 72(1):12-23.
    View in: PubMed
    Score: 0.004
  25. Chiriva-Internati M, Yu Y, Mirandola L, Jenkins MR, Chapman C, Cannon M, Cobos E, Kast WM. Cancer testis antigen vaccination affords long-term protection in a murine model of ovarian cancer. PLoS One. 2010 May 12; 5(5):e10471.
    View in: PubMed
    Score: 0.004
  26. Bellone S, Anfossi S, O'Brien TJ, Cannon MJ, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD. Induction of human tumor-associated differentially expressed gene-12 (TADG-12/TMPRSS3)-specific cytotoxic T lymphocytes in human lymphocyte antigen-A2.1-positive healthy donors and patients with advanced ovarian cancer. Cancer. 2009 Feb 15; 115(4):800-11.
    View in: PubMed
    Score: 0.003
  27. Yu Y, Pilgrim P, Zhou W, Gagliano N, Frezza EE, Jenkins M, Weidanz JA, Lustgarten J, Cannon M, Bumm K, Cobos E, Kast WM, Chiriva-Internati M. rAAV/Her-2/neu loading of dendritic cells for a potent cellular-mediated MHC class I restricted immune response against ovarian cancer. Viral Immunol. 2008 Dec; 21(4):435-42.
    View in: PubMed
    Score: 0.003
  28. Bellone S, Anfossi S, O'Brien TJ, Cannon MJ, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD. Generation of CA125-specific cytotoxic T lymphocytes in human leukocyte antigen-A2.1-positive healthy donors and patients with advanced ovarian cancer. Am J Obstet Gynecol. 2009 Jan; 200(1):75.e1-10.
    View in: PubMed
    Score: 0.003
  29. Yu Y, Pilgrim P, Yan J, Zhou W, Jenkins M, Gagliano N, Bumm K, Cannon M, Milzani A, Dalle-Donne I, Kast WM, Cobos E, Chiriva-Internati M. Protective CD8+ T-cell responses to cytomegalovirus driven by rAAV/GFP/IE1 loading of dendritic cells. J Transl Med. 2008 Oct 05; 6:56.
    View in: PubMed
    Score: 0.003
  30. Bellone S, Pecorelli S, Cannon MJ, Santin AD. Advances in dendritic-cell-based therapeutic vaccines for cervical cancer. Expert Rev Anticancer Ther. 2007 Oct; 7(10):1473-86.
    View in: PubMed
    Score: 0.003
  31. Pashov A, Monzavi-Karbassi B, Chow M, Cannon M, Kieber-Emmons T. Immune surveillance as a rationale for immunotherapy? Hum Vaccin. 2007 Sep-Oct; 3(5):224-8.
    View in: PubMed
    Score: 0.003
  32. Kim KH, Dishongh R, Santin AD, Cannon MJ, Bellone S, Nakagawa M. Recognition of a cervical cancer derived tumor cell line by a human papillomavirus type 16 E6 52-61-specific CD8 T cell clone. Cancer Immun. 2006 Jun 30; 6:9.
    View in: PubMed
    Score: 0.003
  33. Bellone S, Watts K, Cane' S, Palmieri M, Cannon MJ, Burnett A, Roman JJ, Pecorelli S, Santin AD. High serum levels of interleukin-6 in endometrial carcinoma are associated with uterine serous papillary histology, a highly aggressive and chemotherapy-resistant variant of endometrial cancer. Gynecol Oncol. 2005 Jul; 98(1):92-8.
    View in: PubMed
    Score: 0.003
  34. Santin AD, Can? S, Bellone S, Palmieri M, Siegel ER, Thomas M, Roman JJ, Burnett A, Cannon MJ, Pecorelli S. Treatment of chemotherapy-resistant human ovarian cancer xenografts in C.B-17/SCID mice by intraperitoneal administration of Clostridium perfringens enterotoxin. Cancer Res. 2005 May 15; 65(10):4334-42.
    View in: PubMed
    Score: 0.003
  35. Wahid R, Cannon MJ, Chow M. Virus-specific CD4+ and CD8+ cytotoxic T-cell responses and long-term T-cell memory in individuals vaccinated against polio. J Virol. 2005 May; 79(10):5988-95.
    View in: PubMed
    Score: 0.003
  36. Santin AD, Bellone S, Siegel ER, Palmieri M, Thomas M, Cannon MJ, Kay HH, Roman JJ, Burnett A, Pecorelli S. Racial differences in the overexpression of epidermal growth factor type II receptor (HER2/neu): a major prognostic indicator in uterine serous papillary cancer. Am J Obstet Gynecol. 2005 Mar; 192(3):813-8.
    View in: PubMed
    Score: 0.003
  37. Rochford R, Cannon MJ, Moormann AM. Endemic Burkitt's lymphoma: a polymicrobial disease? Nat Rev Microbiol. 2005 02; 3(2):182-7.
    View in: PubMed
    Score: 0.003
  38. Santin AD, Zhan F, Bignotti E, Siegel ER, Can? S, Bellone S, Palmieri M, Anfossi S, Thomas M, Burnett A, Kay HH, Roman JJ, O'Brien TJ, Tian E, Cannon MJ, Shaughnessy J, Pecorelli S. Gene expression profiles of primary HPV16- and HPV18-infected early stage cervical cancers and normal cervical epithelium: identification of novel candidate molecular markers for cervical cancer diagnosis and therapy. Virology. 2005 Jan 20; 331(2):269-91.
    View in: PubMed
    Score: 0.003
  39. Crew MD, Cannon MJ, Phanavanh B, Garcia-Borges CN. An HLA-E single chain trimer inhibits human NK cell reactivity towards porcine cells. Mol Immunol. 2005 Jun; 42(10):1205-14.
    View in: PubMed
    Score: 0.003
  40. Wahid R, Cannon MJ, Chow M. Dendritic cells and macrophages are productively infected by poliovirus. J Virol. 2005 Jan; 79(1):401-9.
    View in: PubMed
    Score: 0.003
  41. Santin AD, Bellone S, Roman JJ, Burnett A, Cannon MJ, Pecorelli S. Therapeutic vaccines for cervical cancer: dendritic cell-based immunotherapy. Curr Pharm Des. 2005; 11(27):3485-500.
    View in: PubMed
    Score: 0.003
  42. Santin AD, Zhan F, Bellone S, Palmieri M, Cane S, Bignotti E, Anfossi S, Gokden M, Dunn D, Roman JJ, O'Brien TJ, Tian E, Cannon MJ, Shaughnessy J, Pecorelli S. Gene expression profiles in primary ovarian serous papillary tumors and normal ovarian epithelium: identification of candidate molecular markers for ovarian cancer diagnosis and therapy. Int J Cancer. 2004 Oct 20; 112(1):14-25.
    View in: PubMed
    Score: 0.003
  43. Santin AD, Bellone S, O'Brien TJ, Pecorelli S, Cannon MJ, Roman JJ. Current treatment options for endometrial cancer. Expert Rev Anticancer Ther. 2004 Aug; 4(4):679-89.
    View in: PubMed
    Score: 0.003
  44. Santin AD, Ravindranath MH, Bellone S, Muthugounder S, Palmieri M, O'Brien TJ, Roman J, Cannon MJ, Pecorelli S. Increased levels of gangliosides in the plasma and ascitic fluid of patients with advanced ovarian cancer. BJOG. 2004 Jun; 111(6):613-8.
    View in: PubMed
    Score: 0.002
  45. Can? S, Bignotti E, Bellone S, Palmieri M, De las Casas L, Roman JJ, Pecorelli S, Cannon MJ, O'brien T, Santin AD. The novel serine protease tumor-associated differentially expressed gene-14 (KLK8/Neuropsin/Ovasin) is highly overexpressed in cervical cancer. Am J Obstet Gynecol. 2004 Jan; 190(1):60-6.
    View in: PubMed
    Score: 0.002
  46. Bellone S, Palmieri M, Gokden M, Joshua J, Roman JJ, Pecorelli S, Cannon MJ, Santin AD. Selection of HER-2/neu-positive tumor cells in early stage cervical cancer: implications for Herceptin-mediated therapy. Gynecol Oncol. 2003 Oct; 91(1):231-40.
    View in: PubMed
    Score: 0.002
  47. Kass R, Bellone S, Palmieri M, Can? S, Bignotti E, Henry-Tillman R, Hutchins L, Cannon MJ, Klimberg S, Santin AD. Restoration of tumor-specific HLA class I restricted cytotoxicity in tumor infiltrating lymphocytes of advanced breast cancer patients by in vitro stimulation with tumor antigen-pulsed autologous dendritic cells. Breast Cancer Res Treat. 2003 Aug; 80(3):275-85.
    View in: PubMed
    Score: 0.002
  48. Kass R, Agha J, Bellone S, Palmieri M, Can? S, Bignotti E, Henry-Tillman R, Hutchins L, Cannon MJ, Klimberg S, Santin AD. In vitro induction of tumor-specific HLA class I-restricted CD8+ cytotoxic T lymphocytes from patients with locally advanced breast cancer by tumor antigen-pulsed autologous dendritic cells. J Surg Res. 2003 Jun 15; 112(2):189-97.
    View in: PubMed
    Score: 0.002
  49. Santin AD, Bellone S, Palmieri M, Bossini B, Roman JJ, Cannon MJ, Bignotti E, Can? S, Pecorelli S. Induction of tumor-specific cytotoxicity in tumor infiltrating lymphocytes by HPV16 and HPV18 E7-pulsed autologous dendritic cells in patients with cancer of the uterine cervix. Gynecol Oncol. 2003 May; 89(2):271-80.
    View in: PubMed
    Score: 0.002
  50. Santin AD, Bellone S, Palmieri M, Bossini B, Dunn D, Roman JJ, Pecorelli S, Cannon M, Parham GP. Effect of blood transfusion during radiotherapy on the immune function of patients with cancer of the uterine cervix: role of interleukin-10. Int J Radiat Oncol Biol Phys. 2002 Dec 01; 54(5):1345-55.
    View in: PubMed
    Score: 0.002
  51. Santin AD, Bellone S, Gokden M, Cannon MJ, Parham GP. Vaccination with HPV-18 E7-pulsed dendritic cells in a patient with metastatic cervical cancer. N Engl J Med. 2002 May 30; 346(22):1752-3.
    View in: PubMed
    Score: 0.002
  52. Santin AD, Bellone S, Gokden M, Palmieri M, Dunn D, Agha J, Roman JJ, Hutchins L, Pecorelli S, O'Brien T, Cannon MJ, Parham GP. Overexpression of HER-2/neu in uterine serous papillary cancer. Clin Cancer Res. 2002 May; 8(5):1271-9.
    View in: PubMed
    Score: 0.002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.